Fabio Fimiani

Dr. Fabio Fimiani

Unit of Inherited and Rare Cardiovascular Diseases, A.O.R.N. Dei Colli “V. Monaldi”, Naples, Italy.
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2014 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
EGEnrica Golia
Enrica Golia
Giuseppe LimongelliGiuseppe Limongelli
Giuseppe Limongelli
FNFrancesco Natale
Francesco Natale
FFFabio Fimiani
Fabio Fimiani
VMValeria Maddaloni
Valeria Maddaloni
Paolo CalabròPaolo Calabrò
Paolo Calabrò

1 January 2017 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
Felice GragnanoFelice Gragnano
Felice Gragnano
Simona SperlonganoSimona Sperlongano
Simona Sperlongano
EGEnrica Golia
Enrica Golia
FNFrancesco Natale
Francesco Natale
RBRenatomaria Bianchi
Renatomaria Bianchi
Paolo CalabròPaolo Calabrò
Paolo Calabrò
Beyond its role in hemostasis, von Willebrand factor (VWF) is an emerging mediator of vascular inflammation. Recent studies highlight the involvement of VWF and its regulator, ADAMTS13, in mechanisms that underlie vascular inflammation and immunothrombosis, like leukocyte rolling, adhesion, and extravasation; vascular permeability; ischemia/reperfusion injury; complements activation; and NETosis. The VWF/ADAMTS13 axis is implicated in the pathogenesis of atherosclerosis, promoting plaque formation and inflammation through macrophage and neutrophil recruitment in inflamed lesions. Moreover, VWF and ADAMTS13 have been recently proposed as prognostic biomarkers in cardiovascular, metabolic, and inflammatory diseases, such as diabetes, stroke, myocardial infarction, and sepsis. All these features make VWF an attractive therapeutic target in thromboinflammation. Several lines of research have recently investigated “tailor-made” inhibitors of VWF. Results from animal models and clinical studies support the potent anti-inflammatory and antithrombotic effect of VWF antagonism, providing reassuring data on its safety profile. This review describes the role of VWF in vascular inflammation “from bench to bedside” and provides an updated overview of the drugs that can directly interfere with the VWF/ADAMTS13 axis.

Mariarita BrancaccioMariarita Brancaccio
Mariarita Brancaccio
Cristina MennittiCristina Mennitti
Cristina Mennitti
ACArturo Cesaro
Arturo Cesaro
FFFabio Fimiani
Fabio Fimiani
MVMartina Vano
Martina Vano
Olga ScudieroOlga Scudiero
Olga Scudiero
Physical activity, combined with adequate nutrition, is considered a protective factor against cardiovascular disease, musculoskeletal disorders, and intestinal dysbiosis. Achieving optimal performance requires a significantly high energy expenditure, which must be correctly supplied to avoid the occurrence of diseases such as muscle injuries, oxidative stress, and heart pathologies, and a decrease in physical performance during competition. Moreover, in sports activities, the replenishment of water, vitamins, and minerals consumed during training is essential for safeguarding athletes’ health. In this scenario, vitamins play a pivotal role in numerous metabolic reactions and some muscle biochemical adaptation processes induced by sports activity. Vitamins are introduced to the diet because the human body is unable to produce these micronutrients. The aim of this review is to highlight the fundamental role of vitamin supplementation in physical activity. Above all, we focus on the roles of vitamins A, B6, D, E, and K in the prevention and treatment of cardiovascular disorders, muscle injuries, and regulation of the microbiome.

Verified
Journal Article
Open access
PDF file
EMEmanuele Monda
Emanuele Monda
GPGiuseppe Palmiero
Giuseppe Palmiero
MRMarta Rubino
Marta Rubino
FVFederica Verrillo
Federica Verrillo
FAFederica Amodio
Federica Amodio
Giuseppe LimongelliGiuseppe Limongelli
Giuseppe Limongelli
Cardiomyopathies (CMPs) represent a diverse group of heart muscle diseases, grouped into specific morphological and functional phenotypes. CMPs are associated with mutations in sarcomeric and non-sarcomeric genes, with several suspected epigenetic and environmental mechanisms involved in determining penetrance and expressivity. The understanding of the underlying molecular mechanisms of myocardial diseases is fundamental to achieving a proper management and treatment of these disorders. Among these, inflammation seems to play an important role in the pathogenesis of CMPs. The aim of the present study is to review the current knowledge on the role of inflammation and the immune system activation in the pathogenesis of CMPs and to identify potential molecular targets for a tailored anti-inflammatory treatment.

30 January 2020 in BioFactors
Verified
Journal Article
Closed access
PDF file
ACArturo Cesaro
Arturo Cesaro
VBVanessa Bianconi
Vanessa Bianconi
FGFelice Gragnano
Felice Gragnano
EMElisabetta Moscarella
Elisabetta Moscarella
FFFabio Fimiani
Fabio Fimiani
Paolo CalabròPaolo Calabrò
Paolo Calabrò

Olga ScudieroOlga Scudiero
Olga Scudiero
BLBarbara Lombardo
Barbara Lombardo
Mariarita BrancaccioMariarita Brancaccio
Mariarita Brancaccio
Cristina MennittiCristina Mennitti
Cristina Mennitti
ACArturo Cesaro
Arturo Cesaro
Giulia FrissoGiulia Frisso
Giulia Frisso
Coronaviruses (CoVs) represent a large family of RNA viruses that can infect different living species, posing a global threat to human health. CoVs can evade the immune response, replicate within the host, and cause a rapid immune compromise culminating in severe acute respiratory syndrome. In humans, the immune system functions are influenced by physical activity, nutrition, and the absence of respiratory or cardiovascular diseases. This review provides an in-depth study between the interactions of the immune system and coronaviruses in the host to defend against CoVs disease.